Skip to main content
. 2018 Nov 21;9:4904. doi: 10.1038/s41467-018-07334-3

Fig. 4.

Fig. 4

Tissue Immunofluorescence imaging of total EGFR and phosphorylated-EGFR (p-EGFR) in brain and flank tumors. a Images showing total EGFR in brain and flank tumors (red) overlaid with Hoechst (blue), treated with placebo, low (33 mg kg−1) and high (100 mg kg−1) dose erlotinib, and graphs (on right) showing quantitative analysis EGFR levels over whole tumor region in each treatment group. b Images showing p-EGFR in brain and flank tumors (red) overlaid with Hoechst (blue), with placebo, low (33 mg kg−1) and high (100 mg kg−1) dose erlotinib and graphs (on right) showing average (mean) intensity of p- EGFR levels in each treatment group. (scalebars on images represent 250 µm, error bars represent 1 standard deviation, n = 2 for brain, n = 3 for flank)